Woodland Biosciences
8.0/10 Overall Rating
No Reviews Yet
5 Orders Completed
Worcester, Massachusetts, US
Woodland Biosciences is a preclinical contract research organization (CRO). Originally located on the campus of Tufts Veterinary Medicine School in North Grafton, MA, in 2020 we joined Ichor Therapeutics in LaFayette, NY to increase capacity, capabilities and to remain an essential business to stay open for our clients and partners. We deliver and develop human disease relevant in vivo, preclinical, and efficacy modeling services for oncology & metabolic diseases in an AAALAC-accredited facility. We offer xenografts in select solid tumors, and the "STZ/HFD" NASH model in both male and female as well as CCl4 and TAA fibrosis and can customize protocols to your needs. Orthotopic and syngeneic models available with a focus on liver and pancreatic cancers. We have many partners rounding out a full discovery and preclinical offering.
NASH (Non-Alcoholic Steatohepatitis)
STZ + HFD induced. Moderate fibrosis in males. Extra chemical hit provides robust scores in females.
Carbon tetrachloride-induced liver fibrosis in mouse - CCl4 model
Thioacetamide-induced liver fibrosis in mouse or rats - TAA model
The standard readouts of liver fibrosis, ballooning degeneration, inflammation assessment and steatosis are routine. We can also run the more extended, high fat diet only model for liver fibrosis (Amylin model) and routinely do DIO (Diet-Induced Obesity) studies for anti-obesity and diabetic drug efficacy.
Colo-205
HT-29 (HTB-38)
HCT-116
C2BBe1(CACO-2)
CACO-2
SW-403
SW-1417
WiDr
SW-48
SW-480
LS-180
LS-174T
Colo-320DM
Colo-320HSR
DLD-1
HCT-15
SW-620
LoVo
Colo-201
SW-948
NCI-H747
NCI-H508
SW-837
SK-CO-1
SW-1116
RKO
GP2d
SNU-C2A
HCT-8
GP5d
T84
LS-411N
UCH-1
UCH-2
SH-SY5Y
CCF-STTG1
HTB-14 = U-87 MG
U-118
U-138
U-251MG
LN-18
A-172
LN-229
T98G
M059J
M059K
The diet-induced obesity model (DIO) is a rapid and efficient means to screen drugs for effects on weight loss.
IPGTT or OGTT analysis in normal, fat or diabetic mouse and rat models are available.
UNKC-6141 Syngeneic C57Bl/6 - IO model
L3.6pl
CAPAN-1
MiaPaCa-2
PANC-1
BxPC-3
CRL-1997 / HPAF-II
PL-45
PANC-10.05
AsPC-1
HPAC
PA-TU-8988S
PA-TU-8988T
PA-TU-8902
Liver Cancer (HCC) Xenografts - Orthotropic and Flank
MHCC-97H - Highly metastatic to lung
MHCC-97L
MHCC-97L-M6
SNU-398
SNU-449
SNU-182
SNU-475
SNU-387
SNU-423
Hep-3B
HEP-G2
HTB-52 / SK-HEP-1
CRL-11997 / HEP-G2/2.2.1
CRL-11233 / THLE-3
CRL-10741 / C3A
NeHepLxHT
BEL 7402
LS-11
SMMC 7721
Woodland has a number of human liver cancer (HCC predominantly) tumors banked. In addition, we have started to collect pancreatic cancer tumors and have a few growing. We have one patient GBM that has been successfully used in vitro.
We have a number of human cell lines (>400 AVAILABLE) not all are capable of forming tumors in animals, but inquire if you are interested in a specific line. In addition, we have 6 syngeneic (mouse tumors in immune-competent mice) - see our website for more details.
Woodland has experience in timed necropsies with up to 31 different tissues / organs removed and stored properly for histology, RNA or protein analyses. These can be done timed to match drug administration with precision. For the 31 tissues, we were able to have a whole team capable of doing this within 20 minutes per animal, staged necropsy so that organs like liver were taken first to maximize integrity of the samples.
See our cancer modeling for a fairly comprehensive list of cell lines we use for CDX modeling. Many have growth curves.
Drug Discovery & Development Services
Drug Discovery Services
Lead Identification and Validation Services
Xenograft Models Services
Model Organisms Services
Mammalian Models Services
Rodent Models Services
Mouse Models Services
Woodland Biosciences has not received any reviews.
Woodland Biosciences has not received any endorsements.